These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34170403)

  • 21. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    Foong YC; Merlo D; Gresle M; Buzzard K; Zhong M; Yeh WZ; Jokubaitis V; Monif M; Skibina O; Ozakbas S; Patti F; Grammond P; Amato MP; Kalincik T; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Lechner Scott J; Boz C; Sa MJ; Butzkueven H; van der Walt A; Zhu C;
    J Neurol Neurosurg Psychiatry; 2024 Jul; 95(8):767-774. PubMed ID: 38453478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.
    Moser T; Foettinger F; Hitzl W; Novotna B; Berger T; Bsteh G; Di Pauli F; Hegen H; Kornek B; Langenscheidt D; Sellner J
    Ann Clin Transl Neurol; 2024 Jun; 11(6):1442-1455. PubMed ID: 38715245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    Iaffaldano P; Lucisano G; Guerra T; Patti F; Cocco E; De Luca G; Brescia Morra V; Pozzilli C; Zaffaroni M; Ferraro D; Gasperini C; Salemi G; Bergamaschi R; Lus G; Inglese M; Romano S; Bellantonio P; Di Monte E; Maniscalco GT; Conte A; Lugaresi A; Vianello M; Torri Clerici VLA; Di Sapio A; Pesci I; Granella F; Totaro R; Marfia GA; Danni MC; Cavalla P; Valentino P; Aguglia U; Montepietra S; Ferraro E; Protti A; Spitaleri D; Avolio C; De Riz M; Maimone D; Cavaletti G; Gazzola P; Tedeschi G; Sessa M; Rovaris M; Di Palma F; Gatto M; Cargnelutti D; De Robertis F; Logullo FO; Rini A; Meucci G; Ardito B; Banfi P; Nasuelli D; Paolicelli D; Rocca MA; Portaccio E; Chisari CG; Fenu G; Onofrj M; Carotenuto A; Ruggieri S; Tortorella C; Ragonese P; Nica M; Amato MP; Filippi M; Trojano M;
    J Neurol; 2024 Mar; 271(3):1150-1159. PubMed ID: 38135850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
    BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2024 Jun; 271(6):3142-3152. PubMed ID: 38430270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
    Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
    Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
    López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
    Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
    Müller J; Roos I; Kalincik T; Lorscheider J; Galli E; Benkert P; Schädelin S; Sharmin S; Einsiedler M; Hänni P; Schmid J; Kuhle J; Derfuss T; Granziera C; Ziemssen T; Siepmann T; Yaldizli Ö
    Brain Behav; 2024 May; 14(5):e3498. PubMed ID: 38688877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.